Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K C Marsh

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|August 25, 2001
Discovery of potent antagonists of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 3. Amide (C-ring) structure-activity relationship and improvement of overall properties of arylthio cinnamidesZ Pei, Z Xin, G Liu, et al.
Biochemical and Biophysical Research Communications|August 14, 1996
Novel azacyclic ureas that are potent inhibitors of HIV-1 proteaseH L Sham, C Zhao, K C Marsh, et al.
European Journal of Pharmacology|March 19, 1999
Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptorJ R Wu-Wong, D B Dixon, W J Chiou, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1997
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavirD J Kempf, K C Marsh, G Kumar, et al.
Journal of Medicinal Chemistry|August 14, 1998
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546)G Liu, K J Henry, B G Szczepankiewicz, et al.
Journal of Medicinal Chemistry|October 5, 2001
Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamidesG D Zhu, D L Arendsen, I W Gunawardana, et al.
Journal of Medicinal Chemistry|March 4, 1998
Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacyD J Kempf, H L Sham, K C Marsh, et al.
Bioorganic & Medicinal Chemistry|July 31, 1999
Discovery of a series of pyrrolidine-based endothelin receptor antagonists with enhanced ET(A) receptor selectivityS A Boyd, R A Mantei, A S Tasker, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1996
Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonistT J Opgenorth, A L Adler, S V Calzadilla, et al.
Journal of Medicinal Chemistry|March 1, 1996
2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722M Winn, T W von Geldern, T J Opgenorth, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|August 25, 2001
Discovery of potent antagonists of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 3. Amide (C-ring) structure-activity relationship and improvement of overall properties of arylthio cinnamidesZ Pei, Z Xin, G Liu, et al.
Biochemical and Biophysical Research Communications|August 14, 1996
Novel azacyclic ureas that are potent inhibitors of HIV-1 proteaseH L Sham, C Zhao, K C Marsh, et al.
European Journal of Pharmacology|March 19, 1999
Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptorJ R Wu-Wong, D B Dixon, W J Chiou, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1997
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavirD J Kempf, K C Marsh, G Kumar, et al.
Journal of Medicinal Chemistry|August 14, 1998
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546)G Liu, K J Henry, B G Szczepankiewicz, et al.
Journal of Medicinal Chemistry|October 5, 2001
Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamidesG D Zhu, D L Arendsen, I W Gunawardana, et al.
Journal of Medicinal Chemistry|March 4, 1998
Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacyD J Kempf, H L Sham, K C Marsh, et al.
Bioorganic & Medicinal Chemistry|July 31, 1999
Discovery of a series of pyrrolidine-based endothelin receptor antagonists with enhanced ET(A) receptor selectivityS A Boyd, R A Mantei, A S Tasker, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1996
Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonistT J Opgenorth, A L Adler, S V Calzadilla, et al.
Journal of Medicinal Chemistry|March 1, 1996
2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722M Winn, T W von Geldern, T J Opgenorth, et al.
Pageof 5